SUZHOU,

苏州，

China

中国

,

，

April 10, 2025

2025年4月10日

/PRNewswire/ -- EonveLab, a subsidiary of ImmVira Group ('ImmVira,' or the 'Company'), recently announced that its in-house developed engineered exosome product, MVR-EX103, developed for treating superficial skin depressions, has successfully passed the review of the International Cosmetic Ingredient Nomenclature Committee ('INC') and been officially granted a standardized International Nomenclature Cosmetic Ingredient ('INCI') name under the designation 'Exosome.' This marks the first engineered exosome worldwide to receive an INCI designation, highlighting ImmVira's leadership in the field and a significant advancement in the development of next-generation cosmetic ingredients..

/PRNewswire/ -- 近日，ImmVira集团（“ImmVira”或“公司”）旗下子公司EonveLab宣布，其自主研发的用于治疗浅表性皮肤凹陷的工程外泌体产品MVR-EX103成功通过国际化妆品成分命名委员会（“INC”）的审核，并被正式授予名为“Exosome”的国际化妆品成分（“INCI”）标准化名称。这标志着MVR-EX103成为全球首款获得INCI命名的工程外泌体，彰显了ImmVira在该领域的领导地位，并在下一代化妆品原料开发中取得了重要进展。

As a globally recognized regulatory standard, the INCI system has been widely adopted across major markets, including the U.S., EU, and

作为全球公认的监管标准，INCI系统已被包括美国、欧盟等主要市场广泛采用，

China

中国

. The INCI system ensures reliable safeguards for transparency and consistency, which facilitates international regulatory compliance while enhancing consumer trust through ingredient labeling clarity and formulation safety.

INCI系统确保了透明度和一致性的可靠保障，这有助于国际法规的遵守，同时通过成分标签的清晰度和配方安全性增强了消费者的信任。

Based on its OVPENS platform, ImmVira has developed a series of engineered exosome pipelines capable of simultaneous multi-protein delivery, targeting critical unmet medical needs in complex chronic and anti-aging related diseases. Compared to naturally derived exosomes, engineered exosomes offer advantages, including consistency and controllability in quality derived from stable cell lines, precise and stable therapeutic function benefiting from the precisely .

基于其OVPENS平台，英沐维拉开发了一系列能够同时递送多种蛋白质的工程外泌体管线，针对复杂慢性病和抗衰老相关疾病中关键未满足的医疗需求。与天然来源的外泌体相比，工程外泌体具有多项优势，包括源于稳定细胞系的质量一致性与可控性，以及得益于精确设计的精准且稳定的治疗功能。

designed

设计的

targeting functional proteins, and scalable GMP-standard manufacturing under strict supervision. The approval of MVR-EX103 by INCI is a significant milestone for the Company in advancing international partner

靶向功能性蛋白质，并在严格监督下进行可扩展的GMP标准制造。MVR-EX103获得INCI批准是公司在推进国际合作伙伴方面的重要里程碑。

ships

船

and market expansion. ImmVira has entered a commercial partnership with a leading multinational corporation for the U.S. and Canadian markets of MVR-EX103. Meanwhile, more expansive global collaborative efforts are currently underway and progressing steadily.

和市场扩张。ImmVira已与一家领先的跨国公司就MVR-EX103的美国和加拿大市场达成了商业合作伙伴关系。同时，更广泛的合作努力正在进行中，并且进展顺利。

Unlike conventional injectables, topical engineered exosome products designed for pan-dermatological applications benefit from a flexible and expedited registration pathway, enabling direct-to-market commercialization through the filing of cosmetic ingredients. Going forward, with the commitment to technology-driven development, ImmVira is poised to expand its engineered exosome applications across multiple sectors, driving the in-depth integration of both the healthcare and beauty industries.

与传统的注射剂不同，为泛皮肤科应用设计的外用工程外泌体产品得益于灵活且加速的注册途径，可以通过提交化妆品成分直接实现市场化。未来，凭借对技术驱动发展的承诺，ImmVira准备将其工程外泌体应用扩展到多个领域，推动医疗和美容行业的深度融合。

Through cutting-edge science and scalable solutions, ImmVira aims to deliver a new generation of safe, effective, and globally accessible cosmetic ingredients and skincare solutions..

通过前沿科学和可扩展的解决方案，ImmVira致力于提供新一代安全、有效且全球可及的化妆品成分和护肤解决方案。

About ImmVira

关于亦诺微

ImmVira is a global biotech company dedicated to developing breakthrough therapeutic solutions through efficient, safe, and targeted drug delivery technologies. The company centers its operations on the end-to-end drug development platform (OVPENS Platform) and has established an innovative R&D system that powers two robust delivery vectors: engineered oncolytic viruses and engineered exosomes.

ImmVira是一家全球生物技术公司，致力于通过高效、安全和靶向的药物递送技术开发突破性的治疗解决方案。公司围绕端到端药物开发平台（OVPENS平台）开展业务，并建立了创新的研发体系，推动两大强大的递送载体：工程化溶瘤病毒和工程化外泌体。

With an established CMC process in line with global standards, the platform originated multiple innovative drug candidates targeting major, complex, and refractory diseases, including cancer, respiratory diseases, metabolic disorders, neurodegenerative diseases, urological diseases, and dermatological conditions.

凭借符合全球标准的既定CMC流程，该平台推出了多个针对重大、复杂和难治性疾病（包括癌症、呼吸系统疾病、代谢紊乱、神经退行性疾病、泌尿系统疾病和皮肤病）的创新候选药物。

Based on extensive research and development, ImmVira has pioneered, developed, and matured both the field of oncolytic viruses for cancer therapy and the field of engineered exosomes for non-cancer applications..

基于广泛的研发工作，ImmVira率先开发并成熟了用于癌症治疗的溶瘤病毒领域和用于非癌症应用的工程外泌体领域。

SOURCE ImmVira

源代码 ImmVira

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

网红

9k+

9千+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用